Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
FDA Clears CU Anschutz Clinical Trial Using Engineered Immune Cells to Fight Colorectal Cancer
2+ day, 16+ hour ago (836+ words) CAR T-cells developed at CU Anschutz will target two pathways that help colorectal tumors grow and evade the immune system AURORA, Colo., Sept. 10, 2026 /PRNewswire/ -- The U.S. Food and Drug Administration has granted permission for investigators at the University of Colorado Anschutz…...
PSA and Grade Reveal Who Benefits Most from PSMA SPECT/CT Staging
24+ min ago (103+ words) Prostate cancer is the most commonly diagnosed cancer in men in many countries, and the moment of diagnosis triggers a cascade of decisions that will shape a patient’s entire treatment trajectory. Central to those decisions is one deceptively simple question:…...
Commentary Challenges Claims of Exceptional Melflufen Responses in Multiple
38+ min ago (746+ words) A new commentary published in the Journal of Cancer Research and Clinical Oncology is challenging how exceptional individual responses to an experimental multiple myeloma drug should be interpreted, warning that remarkable case reports can inadvertently obscure evidence that a treatment…...
Sleep, Exercise, and Support May Shield Cancer Caregivers From Mental
42+ min ago (809+ words) Caring for a loved one through cancer is one of the most emotionally demanding roles in modern medicine, and a new nationwide analysis confirms just how heavy that burden can be....
Bispecific Antibody Meets Antibody-Drug Conjugate in Promising Small Cell
53+ min ago (770+ words) Small cell lung cancer has long been one of the most difficult malignancies to treat, marked by aggressive growth, early dissemination and a stubborn tendency to develop resistance to standard therapies....
Dual Immunotherapy Edges Out Pembrolizumab in Cost-Effectiveness for
54+ min ago (649+ words) A new health economic analysis has found that the combination of nivolumab plus ipilimumab, a dual immune checkpoint inhibitor regimen, may deliver more quality-adjusted life years at lower total cost than pembrolizumab, the currently recommended first-line immunotherapy, for patients with…...
Truth about blood cancer remission: Why relapse happens and how to monitor it?
1+ day, 47+ min ago (65+ words) Even when patients are told that they are in total remission, in some cases, there are chances of a relapse. However, it doesn't imply all patients may suffer a relapse. Frequent monitoring and early reporting of any unusual symptoms can…...
Lab Models Take Center Stage in the Race to Improve Cancer Immunotherapy
1+ hour, 18+ min ago (583+ words) Cancer immunotherapy has transformed the treatment landscape for many patients with solid tumors, delivering durable responses in diseases that once resisted nearly every therapeutic approach....
Cholangioscopy Shows Strong Accuracy for Detecting Bile Duct Cancer
1+ hour, 45+ min ago (621+ words) For patients facing the terrifying possibility of bile duct cancer, the diagnostic journey is often exhausting and inconclusive. Scans can reveal a blockage, but they cannot tell doctors whether it is caused by a tumor, scarring, or inflammation....
Immune Side Effects May Signal Stronger Tumor Shrinkage and Longer Survival
2+ hour, 35+ min ago (628+ words) When patients with advanced gastric cancer receive immune checkpoint inhibitors, one of the most puzzling phenomena in modern oncology is the apparent paradox that side effects can be good news....